Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, June 14, 2024 | Back issues
Courthouse News Service Courthouse News Service

Pharma Class Action

SAN FRANCISCO - Shareholders claim Clovis Oncology goosed its share price with false and misleading reports about its rociletinib drug, and shares fell from $69.19 to $30.24 on Nov. 16 when the truth came out, in Federal Court.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.